Program
CM336
A development code. Also written as “CM336 Injection”, “CM336 Injection(Low dose group)” and “CM336 Injection(High dose group)”.
Its studies are mostly in Multiple Myeloma · Purpura, Thrombocytopenic, Idiopathic · Amyloidosis, led by Keymed Biosciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciences | 55 open or running | phase 3since Sep 12, 2025 | Jun 18, 2025 | Sep 2027phase 3 · NCT07181239 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 18, 2025First study: phase 2 study in Primary Light-Chain AmyloidosisFirst studyNCT07039578 · 90 planned · China
- Aug 29, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07175493 · 158 planned · China
- Sep 12, 2025Phase 3 study in Multiple MyelomaNCT07181239 · 280 planned · China
- Jun 8, 2026Phase 1 study in Primary Sjögren's Syndrome (pSS)NCT07642843 · 30 planned · China
- Oct 27, 2026Phase 3 study in Multiple MyelomaNCT07910903 · 320 planned · China
Ahead
- Sep 2027Primary completion: phase 3 study in Multiple MyelomaNCT07181239
- Nov 18, 2027Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07175493
- Apr 2028Primary completion: phase 1 study in Primary Sjögren's Syndrome (pSS)NCT07642843
- May 2030Primary completion: phase 3 study in Multiple MyelomaNCT07910903
TargetBeta
“The goal of this clinical trial is to evaluate whether CM336, a BCMA/CD3 bispecific antibody, in combination with daratumumab and lenalidomide can induce deep and durable responses in adults with transplant-ineligible newly diagnosed multiple myeloma (NDMM).”study text, by rule · the study
Other programs on CD3E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etentamig | AbbVie | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| cevostamab | Hoffmann-La Roche | phase 3 | 8 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| pasritamig | Johnson & Johnson | phase 3 | 5 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07910903Multiple Myeloma · China | 3 | Not yet recruiting | May 2030 | 320 |
| NCT07642843Primary Sjögren's Syndrome (pSS) · China | 1 | Not yet recruiting | Apr 2028 | 30 |
| NCT07181239Multiple Myeloma · China | 3 | Not yet recruiting | Sep 2027 | 280 |
| NCT07175493Purpura, Thrombocytopenic, Idiopathic · China | 2 | Recruiting | Nov 18, 2027 | 158 |
| NCT07039578Primary Light-Chain Amyloidosis · China | 2 | Recruiting | Jun 30, 2026 | 90 |
How it is read
Names in the registry
- “CM336”, 2 entries
- “CM336 Injection”, 2 entries
- “CM336 Injection(Low dose group)”, 1 entry
- “CM336 Injection(High dose group)”, 1 entry
Codes read as this program: CM336.
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Amyloidosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.